Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-31
Abstract Views: 265
Views PDF (Tiếng Việt): 309
DOI: https://doi.org/10.52852/tcncyh.v162i1.1407
Issue
Vol. 162 No. 1 (2023)
Section
Các bài báo
How to Cite
Thị Quỳnh Nhung, B., Thị Vân Anh, P., Trọng Thông, N., Ngọc Cương, L., & Phương Thanh, M. (2023). 31. Antifibrotic effects of vismisco on carbon tetrachloride-induced liver cirrhosis in mice. Journal of Medical Research, 162(1), 272-279. https://doi.org/10.52852/tcncyh.v162i1.1407

31. Antifibrotic effects of vismisco on carbon tetrachloride-induced liver cirrhosis in mice

Bui Thi Quynh Nhung, Pham Thi Van Anh, Nguyen Trong Thong, Luong Ngoc Cuong, Mai Phuong Thanh

Main Article Content

Abstract

In this study, the antifibrotic effects of Vismisco was evaluated in Swiss mice model of CCl4 induced liver cirrhosis. The test drug at the dose of 0.6 and 1.8 g/kg body weight were given by oral gavage for 19 consecutive weeks. Liver inflammation and fibrosis were evaluated by hepatosomatic index, HE staining, MDA and hydroxyproline assays, and biochemical tests. The results demonstrated that the administration of Vismisco was able to limit CCl4-induced liver injury by reducing serum AST and ALT levels, to lower total bilirubin and improve serum albumin and total cholesterol levels, and decrease MDA, Hydroxyproline concentrations in liver homogenate.


 

Article Details

Keywords

Vismisco, cirrhosis, carbon tetrachloride, Swiss mice

References

1. Kamath PS, Shah VH. Overview of Cirrhosis. In: Feldman M, Friedman LS Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease. 10th ed. Philadelphia: Saunders Inc; 2016: 1254-1260.
2. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015; 64(5): 830-841.
3. Đỗ Tất Lợi. Những cây thuốc và vị thuốc Việt Nam. Nhà xuất bản Y học, Hà Nội; 2019: 498-499, 870-871, 932-933.
4. Trần Thúy. Hoàn thiện công nghệ sản xuất 4 bài thuốc y học cổ truyền phục vụ cộng đồng. Báo cáo tổng kết dự án cấp Nhà nước. 2006
5. Closa D, Torres M et al. Prostanoids and free radicals in CCl4-induced hepatotoxicity in rats: Effect of astilbin. Prostaglandins Leukotrienes and Essential Fatty Acids. 1997; 56: 331-334.
6. Talukder A, Choudhury M. Hypoglycaemic activity of Scoparia dulcis L. in different solvent systems. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(3): 330-332.
7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1(5): 431-435.
8. Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. Lab Anim. 2015;49(1 Suppl):4-11.
9. Tạ Thành Văn, Đặng Thị Ngọc Dung. Hóa sinh gan. Nhà xuất bản Y học, Hà Nội, 2021: 363 - 382.
10. Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. Hydroxyproline as a Biomarker in Liver Disease. In: Patel V, Preedy V, eds. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht; 2017: 471-491.
11. Mohd Ali N, Mohd Yusof H, Long K, et al. Antioxidant and Hepatoprotective Effect of Aqueous Extract of Germinated and Fermented Mung Bean on Ethanol-Mediated Liver Damage. BioMed Research International. 2013; 2013: 693613. doi: 10.1155/2013/693613.
12. Xu Q, Wu F, Cao J, et al. Astilbin selectively induces dysfunction of liver-infiltrating cells - novel protection from liver damage. European Journal of Pharmacology. 1999;377(1):93-100.
13. Wang J, Zhao Y, Xu Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-alpha production and T lymphocyte adhesion. Journal of Pharmacy and Pharmacology. 2004; 56: 495- 502.
14. Elayaraja A, Sheikh A, Rahaman Shaik A. Evaluation of Antioxidant and in vitro Antioxidant Activity of Various Extracts of Scoparia dulcis L. J Pharm Sci & Res. 2012;4(2):1724-1727.